RELAPSED/REFRACTORY AML
Clinical trials for RELAPSED/REFRACTORY AML explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY AML trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets tough blood cancers in early trial
Disease control OngoingThis study tests a new drug called bexmarilimab, given together with standard treatments, for people with certain blood cancers (MDS, CMML, or AML). The goal is to first find a safe dose and then see if the combination helps shrink or control the cancer. About 181 adults are taki…
Matched conditions: RELAPSED/REFRACTORY AML
Phase: PHASE1, PHASE2 • Sponsor: Faron Pharmaceuticals Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill takes on tough blood cancers in early trial
Disease control OngoingThis early-stage study tests an oral drug called AUTX-703 in 34 adults with relapsed or hard-to-treat acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The main goal is to check safety and find the right dose. It's an open-label trial, meaning everyone knows they'r…
Matched conditions: RELAPSED/REFRACTORY AML
Phase: PHASE1 • Sponsor: Auron Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New Antibody-Drug conjugate takes aim at tough leukemias
Disease control OngoingThis first-in-human trial tests BYON4413, an antibody-drug conjugate designed to target and kill cancer cells in people with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS). The study involves 16 participants and aims to check safety, how th…
Matched conditions: RELAPSED/REFRACTORY AML
Phase: PHASE1 • Sponsor: Byondis B.V. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC